ProCE Banner Activity

ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM

Slideset Download
Conference Coverage
At the 3-year follow-up, addition of elotuzumab to lenalidomide/dexamethasone reduced risk of disease progression or death by 27%.

Released: December 07, 2015

Expiration: December 05, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen